Trials & Studies

Animal Studies with LDN

The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma

Lodonal™ Trial Update: Nigeria

Immune Therapeutics Inc., through its wholly owed subsidiary TNI BioTech, Intl. completed a 90-day bridging trial for the treatment of patients with HIV AIDS.  The National Agency for Food and Drug Administration and Control (NAFDAC) approval is based on previous clinical data and the Nigeria Bridging Trial. The trial was a single center, open labeled, randomized, bridging study consisting of one hundred and fifty [150] patients of both genders between the ages of 18-60, each of whom was infected with the human immunodeficiency virus (HIV).


The 90-Day Bridging Trial was undertaken at the State Specialist Hospital in Asubiaro, Osogbo, Osun State, Nigeria with the primary objective to confirm Lodonal™ has a beneficial effect on the immune system of immune deficient patients and that it is safe. The trial separated the patients into a Control (placebo) Group and a Treatment Group (which was administered Lodonal™). The efficacy of increasing CD4 count [cell/mm3] between Day-1 and Day-90 by at least 25% was set as the criteria for demonstrating beneficial effect on the immune system.  Safety was demonstrated through quality of life assessment and vitals both of which were not adversely affected. Treatment Group patients were given a daily dose of 4.5-mg/kg of Lodonal™.


The results yielded an averaged increase of 44% increase in CD4 count in the Lodonal™ Treatment Group compared to an 11% increase in the Control Group. Additionally, there were no reported opportunistic infections and no toxicity levels uncovered. 


Liver function remained normal and there was no negative impact on other systems based on blood results. No significant sleep disturbance or vivid dreams were present enough to justify trial discontinuation. No significant adverse CNS, renal, cardiac, hepatic, musculoskeletal, hematopoietic side effects were present.


NAFDAC issued approval of Lodonal™ in April of 2016 as an immune system regulator in the management of HIV patients and the company is now in the process of completing the registration to import the drug into Nigeria.

Questions about our inventory? Reach out today, we’re happy to help.

 
  • Facebook
  • Twitter

Immune Therapeautics, Inc. © 2017 | All Rights Reserved | 2431 Aloma Ave #124 Winter Park, FL 32792 | 1-888-613-8802